---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-26-000019"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2026-05-12T20:07:17+00:00"
generated_at: "2026-05-12T21:25:52.470170+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M

## Summary
- RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.
- GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.
- Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.
- FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.
- Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026.

## SEC filing metadata
- accession: 0001528287-26-000019
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2026-05-12T20:07:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/neuropace-8xkq12026earning.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-26-000019
- JSON: https://secwatch.observer/filing/0001528287-26-000019.json
- Plain text: https://secwatch.observer/filing/0001528287-26-000019.txt

## Key facts
- Earnings Releases
  NeuroPace Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $22.1 million, net income ($6.7) million. Guidance raised.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total revenue of $22.1 million
  - Net income: ($6.7) million
  - Guidance: raised
  - Result: reported results
  source text: forth by specific reference in such filing. --- EX-99 (EX-99.1) --- NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously Assumes 21% to 23% growth in core RNS ® revenue from existing
  evidence_url: https://www.sec.gov/Archives/edgar/data/1528287/000152828726000019/0001528287-26-000019-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.